Augmentation and combination strategies for depression

Journal of Psychopharmacology
Charles DeBattista

Abstract

Treatment-resistant depression represents a common problem, with the vast majority of depressed patients showing incomplete response to antidepressant trials. Augmentation and combination strategies are commonly employed to address this problem, but there are few randomized, controlled studies to guide treatment choice. Indeed, some of the most common augmentation strategies in depression are those with the least controlled evidence. The popularity of bupropion, psychostimulants and atypical antipsychotics as augmentors may not be warranted by existing controlled studies, whereas two less commonly used augmentors-lithium and thyroid hormone- have substantial controlled evidence to support their use. This paper summarizes the state of the evidence for commonly used augmenting strategies and explores preliminary findings for more investigational approaches.

References

Jul 1, 1995·Archives of General Psychiatry·H K ManjiR H Lenox
Feb 1, 1995·The American Journal of Psychiatry·G W AranaM Molloy
Sep 1, 1996·Archives of General Psychiatry·R AronsonC D Naylor
Feb 1, 1996·Journal of Clinical Psychopharmacology·R D Marshall, M R Liebowitz
Jan 1, 1997·Acta Psychiatrica Scandinavica·T G DinanC Berti
Apr 1, 1997·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·L S SchneiderB S Meyers
Apr 1, 1997·The Journal of Clinical Psychiatry·J A BodkinR J Baldessarini
Apr 16, 1998·The Journal of Clinical Psychiatry·A K Ashton, R C Rosen
Apr 19, 2000·Journal of Clinical Psychopharmacology·C DeBattistaA F Schatzberg
May 19, 2000·The Journal of Clinical Psychiatry·A AhokasR Rimón
Jun 30, 2000·The American Journal of Psychiatry·A F SchatzbergP K Shear
Jan 4, 2001·The American Journal of Psychiatry·R C SheltonH Y Meltzer
Mar 7, 2001·The British Journal of Psychiatry : the Journal of Mental Science·M E ThaseR L Rudolph
May 10, 2001·The International Journal of Neuropsychopharmacology·Russell T. Joffe, Stephen T. H. Sokolov
Oct 11, 2001·Journal of Clinical Psychopharmacology·J K BelanoffA F Schatzberg
Feb 2, 2002·Biological Psychiatry·Linda L CarpenterLawrence H Price
Mar 7, 2002·Archives of General Psychiatry·Rajesh NarendranCynthia A Pristach
May 10, 2002·The Journal of Clinical Psychiatry·Claus NormannJörg Walden
Sep 21, 2002·Biological Psychiatry·Joseph K BelanoffAlan F Schatzberg
Jan 25, 2003·Journal of Clinical Psychopharmacology·Charles DeBattistaAlan F Schatzberg
Jan 25, 2003·Journal of Clinical Psychopharmacology·Andrew A NierenbergMaurizio Fava
Sep 16, 2003·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Michael BauerTom Bschor
Jan 8, 2004·Journal of Clinical Psychopharmacology·Charles DeBattistaJennifer Poirier
Jan 20, 2004·The Journal of Clinical Psychiatry·Helen LavretskyCharles F Reynolds
Mar 9, 2004·The Journal of Clinical Psychiatry·UNKNOWN American Diabetes AssociationUNKNOWN North American Association for the Study of Obesity
Apr 6, 2004·Controlled Clinical Trials·A John RushUNKNOWN STAR*D Investigators Group
Apr 21, 2004·The Journal of Clinical Psychiatry·Raymond W LamLakshmi N Yatham
Nov 19, 2004·Depression and Anxiety·Paolo CassanoGiovanni Battista Cassano
Dec 8, 2004·Archives of General Psychiatry·Holger JahnKlaus Wiedemann
Dec 17, 2004·International Clinical Psychopharmacology·John J WorthingtonMark H Pollack
Dec 23, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Feb 9, 2005·Archives of General Psychiatry·Peter J SchmidtDavid R Rubinow
Feb 11, 2005·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·James G BarbeeNowal J Jamhour
Jun 18, 2005·The Journal of Clinical Psychiatry·Melinda L MorganAndrew F Leuchter

❮ Previous
Next ❯

Citations

Nov 17, 2009·Current Psychiatry Reports·Waguih William IsHakMark Hyman Rapaport
May 26, 2012·Current Psychiatry Reports·Cássio M C BottinoSalma R I Ribeiz
Sep 20, 2011·European Journal of Drug Metabolism and Pharmacokinetics·Jillissa C MolnariAlan L Myers
Mar 5, 2011·Biological & Pharmaceutical Bulletin·Jillissa Christine MolnariAlan Lewis Myers
Jul 9, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Cornelius SchüleRainer Rupprecht
Jan 3, 2015·Pharmacology, Biochemistry, and Behavior·Vivian Binder NeisAna Lúcia S Rodrigues
Oct 1, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mauricio P CunhaAna Lúcia S Rodrigues
May 27, 2008·Epilepsy & Behavior : E&B·John J BarryUNKNOWN Advisory Group of the Epilepsy Foundation as part of its Mood Disorder
Sep 8, 2011·Basic & Clinical Pharmacology & Toxicology·Gaurav GulrezArvind Sharma
Nov 3, 2009·Acta Psychiatrica Scandinavica·J Spijker, W A Nolen
May 21, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Michele FornaroPantaleo Fornaro
Jan 6, 2011·Clinical Neuropharmacology·Joseph BergmanVladimir Lerner
Apr 7, 2007·Journal of Clinical Psychopharmacology·Harold W Goforth, Brendan T Carroll
Jan 22, 2010·CNS Drugs·Richard C SheltonSara A Corya
Jul 16, 2010·Journal of Clinical Psychopharmacology·Georgios PaslakisMichael Deuschle
May 21, 2009·CNS Drugs·Charles DeBattista, Jessica Hawkins
Jul 23, 2013·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Jan SpijkerAnton J L M van Balkom

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here